A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

NCT02028455 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

167

Enrollment

OTHER

Sponsor class

Conditions

CD19+ Acute Leukemia

Interventions

BIOLOGICAL: Patient Derived CD19 specific CAR T cells also expressing an EGFRt

Sponsor

Seattle Children's Hospital